KOD Stock Surged 600% in a Year — Here’s Why Biotech Investors Are Still Watching Closely
Not many stocks trade below $11 one year and above $100 the next. Kodiak Sciences did exactly that. The clinical-stage biopharmaceutical company, listed on the Nasdaq under the ticker KOD, has had the kind of twelve months that biotech investors daydream …